SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Leerink Maintains Market Perform Rating on Amgen, Raises Target to $464

Leerink Partners maintained its Market Perform rating on Amgen and raised its price target to $464 per share from $395.

AMGN

Related stories